Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Advanced Lung Cancer

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Neoplasms

Carcinoma, Non-Small-Cell Lung

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

Advanced Malignant Tumors

Advanced Solid Tumor

Locally Advanced or Metastatic Solid Tumors

Advanced Lung Cancer

Advanced Solid Tumor

Brain Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Nasopharyngeal Carcinoma, Recurrence

Anal Canal Carcinoma, Anus Neoplasms

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Advanced Non Small Cell Lung Cancer

Advanced Solid Tumor

Carcinoma, Non-Small-Cell Lung

Mouth Neoplasms

Advanced Solid Tumor

Advanced Biliary Tract Cancer

Carcinoma, Hepatocellular

Advanced Solid Tumor

High-Risk Resectable NSCLC

Advanced Solid Tumors

Treatment-naive Advanced Non-small Cell Lung Cancer

Advanced Solid Tumors

Esophageal Squamous Cell Carcinoma

Clinical Trials

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

JUPITER06

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

TORCH

NeoTOP

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TOGATHER

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma